MikeyMikeMike
:
Most all small cap pharma stock has issues with revenue. It's the cost of research and development that smaller companies have to sustain that causes this.
Analysts are more optimistic about the company's revenue while expecting losses per share stability. They predict Agios Pharmaceuticals' growth to outpace competitors for now, despite a range of varied future estimates.
Lack of insider buying and substantial insider selling in recent months warrants caution for shareholders regarding the company's stocks. Despite decent insider ownership, the absence of recent insider buying raises doubts about future prospects.
Agios Pharmaceuticals Stock Forum
Clinical Trial Breakthrough: Agios' Blood Disorder Drug Outperforms Placebo in Rare Pediatric Disease
Agios Delivers Record PYRUKYND Growth as FDA Decision Looms: Q4 Earnings Deep Dive
$Humacyte (HUMA.US)$ : 🤔
⇨ Human Acellular Vessel (HAV)™
‣ Vascular Trauma
‣ PDUFA: 8/10/24 (BLA)
🗓️ Last Week’s AdCom & PDUFAs:
$Zevra Therapeutics (ZVRA.US)$ : Favorable AdCom 👍
🗳️ 11-5 votes in favor
⇨ Arimoclomol
‣ Niemann-Pick disease type C
‣ AdCom: 8/2/24 (NDA)
$Adaptimmune Therapeutics (ADAP.US)$ : Approved 🎉
⇨ TECELRA (afamitresgene autoleucel)
‣ Synovial sarcoma
‣ PDUFA: 8/4/24 (BLA)
$GlaxoSmithKline (GSK.US)$ : Approved 🎉
⇨ Jemperli
‣ Endometria...
HOW MANY STUPID TRADERS HERE, LOSING AND STILL TRADING 🤔🤔🤔
Bad Demon Trap = Xi Zor Gai 😏
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3 ...
No comment yet